Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

PATIENTS WITH NSAID-ERD HAD
IMPROVEMENT IN KEY MEASURES OF
DISEASE SEVERITY AT WEEK 52

56% Improvement

IN NC SCORE AT WEEK 52 (TRIAL 2: SECONDARY ENDPOINT)

with DUPIXENT Q2W + INCS (n=35) (-1.34 from a baseline score of 2.38) vs 8% improvement with placebo + INCS (n=44) (-0.21 from a baseline score of 2.49) (LSM difference: -1.13 [95% CI: -1.49, -0.77])1

-2.54 Improvement

IN NPS AT WEEK 52 (TRIAL 2: SECONDARY ENDPOINT)

with DUPIXENT Q2W + INCS (n=35) (baseline score 5.87) vs 0.03 worsening with placebo + INCS (n=44) (baseline score 6.06) (LSM difference: -2.57 [95% CI: -3.27, -1.87])1

37% Improvement

IN LMK-CT SCORE AT WEEK 52 (TRIAL 2: SECONDARY ENDPOINT)

with DUPIXENT Q2W + INCS (n=35) (-7.27 from a baseline score of 19.71) vs 2% improvement with placebo + INCS (n=44) (-0.41 from a baseline score of 19.07) (LSM difference: -6.86 [95% CI: -8.62, -5.10])1

27% of patients enrolled in Trial 2 presented with NSAID-ERD.2

  • INCS, intranasal corticosteroids; LMK-CT, Lund-Mackay computed tomography; LSM, least squares mean; NC, nasal congestion/obstruction; NPS, nasal polyps score; NSAID-ERD, nonsteroidal anti-inflammatory drug–exacerbated respiratory disease; Q2W, once every 2 weeks.

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

References:

  1. Data on file, Sanofi US. LIBERTY NP SINUS-52, CSR. 2018.
  2. DUPIXENT Prescribing Information.